Wei Wang1, Seon Oh1, Mark Koester1, Sandra Abramowicz1, Nan Wang1, Alan R Tall1, Carrie L Welch2. 1. From the Department of Medicine, Division of Molecular Medicine, Columbia University, New York, NY. 2. From the Department of Medicine, Division of Molecular Medicine, Columbia University, New York, NY. cbw13@cumc.columbia.edu.
Abstract
BACKGROUND: Genome-wide association studies for coronary artery disease/myocardial infarction revealed a 58 kb risk locus on 9p21.3. Refined genetic analyses revealed unique haplotype blocks conferring susceptibility to atherosclerosis per se versus risk for acute complications in the presence of underlying coronary artery disease. The cell proliferation inhibitor locus, CDKN2A, maps just upstream of the myocardial infarction risk block, is at least partly regulated by the noncoding RNA, ANRIL, overlapping the risk block, and has been associated with platelet counts in humans. Thus, we tested the hypothesis that CDKN2A deficiency predisposes to increased platelet production, leading to increased platelet activation in the setting of hypercholesterolemia. METHODS AND RESULTS: Platelet production and activation were measured in B6-Ldlr(-/-)Cdkn2a(+/-) mice and a congenic strain carrying the region of homology with the human 9p21.3/CDKN2A locus. The strains exhibit decreased expression of CDKN2A (both p16(INK4a) and p19(ARF)) but not CDKN2B (p15(INK4b)). Compared with B6-Ldlr(-/-) controls, both Cdkn2a-deficient strains exhibited increased platelet counts and bone marrow megakaryopoiesis. The platelet overproduction phenotype was reversed by treatment with cyclin-dependent kinase 4/6 inhibitor, PD0332991/palbociclib, that mimics the endogenous effect of p16(INK4a). Western diet feeding resulted in increased platelet activation, increased thrombin/antithrombin complex, and decreased bleeding times in Cdkn2a-deficient mice compared with controls. CONCLUSIONS: Together, the data suggest that one or more Cdkn2a transcripts modulate platelet production and activity in the setting of hypercholesterolemia, amenable to pharmaceutical intervention. Enhanced platelet production and activation may predispose to arterial thrombosis, suggesting an explanation, at least in part, for the association of 9p21.3 and myocardial infarction.
BACKGROUND: Genome-wide association studies for coronary artery disease/myocardial infarction revealed a 58 kb risk locus on 9p21.3. Refined genetic analyses revealed unique haplotype blocks conferring susceptibility to atherosclerosis per se versus risk for acute complications in the presence of underlying coronary artery disease. The cell proliferation inhibitor locus, CDKN2A, maps just upstream of the myocardial infarction risk block, is at least partly regulated by the noncoding RNA, ANRIL, overlapping the risk block, and has been associated with platelet counts in humans. Thus, we tested the hypothesis that CDKN2A deficiency predisposes to increased platelet production, leading to increased platelet activation in the setting of hypercholesterolemia. METHODS AND RESULTS: Platelet production and activation were measured in B6-Ldlr(-/-)Cdkn2a(+/-) mice and a congenic strain carrying the region of homology with the human 9p21.3/CDKN2A locus. The strains exhibit decreased expression of CDKN2A (both p16(INK4a) and p19(ARF)) but not CDKN2B (p15(INK4b)). Compared with B6-Ldlr(-/-) controls, both Cdkn2a-deficient strains exhibited increased platelet counts and bone marrow megakaryopoiesis. The platelet overproduction phenotype was reversed by treatment with cyclin-dependent kinase 4/6 inhibitor, PD0332991/palbociclib, that mimics the endogenous effect of p16(INK4a). Western diet feeding resulted in increased platelet activation, increased thrombin/antithrombin complex, and decreased bleeding times in Cdkn2a-deficient mice compared with controls. CONCLUSIONS: Together, the data suggest that one or more Cdkn2a transcripts modulate platelet production and activity in the setting of hypercholesterolemia, amenable to pharmaceutical intervention. Enhanced platelet production and activation may predispose to arterial thrombosis, suggesting an explanation, at least in part, for the association of 9p21.3 and myocardial infarction.
Authors: Andrew J Murphy; Mani Akhtari; Sonia Tolani; Tamara Pagler; Nora Bijl; Chao-Ling Kuo; Mi Wang; Marie Sanson; Sandra Abramowicz; Carrie Welch; Andrea E Bochem; Jan Albert Kuivenhoven; Laurent Yvan-Charvet; Alan R Tall Journal: J Clin Invest Date: 2011-10 Impact factor: 14.808
Authors: Jana Matuskova; Anil K Chauhan; Beatrice Cambien; Sophie Astrof; Vandana S Dole; Crystal L Piffath; Richard O Hynes; Denisa D Wagner Journal: Arterioscler Thromb Vasc Biol Date: 2006-03-09 Impact factor: 8.311
Authors: Riyaz S Patel; Folkert W Asselbergs; Arshed A Quyyumi; Tom M Palmer; Chris I Finan; Vinicius Tragante; John Deanfield; Harry Hemingway; Aroon D Hingorani; Michael V Holmes Journal: J Am Coll Cardiol Date: 2014-03-07 Impact factor: 24.094
Authors: Andrew J Murphy; Nora Bijl; Laurent Yvan-Charvet; Carrie B Welch; Neha Bhagwat; Adili Reheman; Yiming Wang; James A Shaw; Ross L Levine; Heyu Ni; Alan R Tall; Nan Wang Journal: Nat Med Date: 2013-04-14 Impact factor: 53.440
Authors: Sergio Martínez-Hervás; Verónica Sánchez-García; Andrea Herrero-Cervera; Ángela Vinué; José Tomás Real; Juan F Ascaso; Deborah Jane Burks; Herminia González-Navarro Journal: J Transl Med Date: 2019-07-12 Impact factor: 5.531
Authors: Yang Tang; Wenli Liu; Wei Wang; Trevor Fidler; Britany Woods; Ross L Levine; Alan R Tall; Nan Wang Journal: Cardiovasc Drugs Ther Date: 2020-04 Impact factor: 3.727